Human Immune Responses to an Adjuvanted H5 Vaccine: Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- 28 Aug 2019 Planned primary completion date changed from 30 May 2019 to 1 Jan 2020.
- 28 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 17 Oct 2018 New trial record